Register Now
Course Information

10th Annual Basic and Clinical Immunology for the Busy Clinician:
COVID-19 and Immune Mediated Inflammatory Diseases: Immunologic, Clinical, Therapeutic and Preventive Strategies at Two Years


The COVID-19 pandemic has had a profound impact on patients with immune-mediated inflammatory diseases (IMIDs). Research is still investigating how the underlying diseases and its therapies, especially targeted agents, affect both the clinical progression of the disease as well as its response to vaccinations. At the same time, significant progress has been made in the early diagnosis, aggressive outpatient management with monoclonal antibodies and antiviral agents, and for hospitalized patients, using immunomodulatory therapies designed to treat IMIDs. Now evidence is accumulating showing that COVID-19 can clearly induce both autoreactivity and autoimmune diseases and may cause long-term symptoms, a syndrome termed “long Covid.”

As a result of the speed and scope of these developments, many practitioners have substantial knowledge gaps regarding these insights into the pathogenesis of COVID-19 and IMIDs, the impact of immunomodulatory therapies and side effects associated with their use, and how to weigh those factors in clinical practice decisions. For this educational activity, the Activity Director and the presenters, all renowned experts in clinical immunology, have identified the following topics as having knowledge and competence gaps among practitioners:

  • Managing COVID-19 in patients with IMIDs
  • Managing IMIDs in the era of COVID-19
  • COVID-19 autoimmunity, prevention, and management
  • Rheumatic diseases and COVID-19

Why Attend the Virtual Symposium?

  • Hear cutting-edge updates and research on the impact of COVID-19 on patients with immune mediated inflammatory diseases
  • Learn from leading experts in the field of immunology
  • Earn CME and ABIM Maintenance of Certification Points
  • Live Q&A panel discussions to supplement the virtual presentations
  • Easy access - participate at your convenience from any location
  • FREE registration!
  • Explore our virtual exhibit hall

After completing this live stream activity, participants will be able to:

  • Describe the pathogenesis of COVID-19 in patients with immune-mediated inflammatory disease including data on the contributions of both disease-specific factors and targeted therapies for disease progression.
  • Critically appraise the risks and benefits of biologic therapies and JAK inhibitors in all patients with immune mediated inflammatory diseases in the COVID-19 era.
  • Summarize recent revisions to major society guidelines for management of IMIDs as they relate to COVID-19.
  • Describe the research on how COVID-19 may induce or alter autoimmune reactivity in both healthy individuals and patients with pre-existing autoimmune diseases.
  • Summarize the clinical implications of data on COVID-19 vaccine responses in patients with an IMID.
  • Describe standards for using monoclonal antibodies in the outpatient management of COVID-19 in high-risk patients with IMIDs.
  • Summarize recent data on COVID-19 vaccine boosters, effects of immunomodulatory therapies, and implications of viral variants in patients with IMIDs.
  • Critically appraise the efficacy and side effect data on agents approved or authorized by the FDA as well as agents showing potential for therapy in critically ill patients with COVID-19 who have inflammatory bowel disease, multiple sclerosis, or dermatologic disorders.

Who Should Attend?

The symposium is directed to rheumatologists, dermatologists, infectious disease, as well as allergists, clinical immunologists, dermatologists, gastroenterologists, neurologists, specialists in integrative medicine, primary care, nurses, physician assistants, and other health care professionals caring for patients with immunologic diseases.